兩家獨立企業由此誕生
生命科學與診斷 & 分析和企業服務

×
×

兩家獨立企業由此誕生

  • 生命科學與診斷業務

    專注於生命科學和診斷業務的高增長型公司,推動科學家和醫療衛生專業人士的研究、發現和檢測,助力打造更健康的世界

  • 分析和企業服務業務

    我們專注於提供全方位的分析和企業服務解決方案,包括領先的OneSource實驗室服務,加速您的科學研究進程

Unconjugated AlphaPlex™ 645 Acceptor Beads, 50 mg | 爱游戏平台注册登录
爱游戏平台注册登录
check quantity

Unconjugated AlphaPlex™ 645 Acceptor Beads, 50 mg

Unconjugated AlphaPlex 645 (Samarium) Acceptor beads bear reactive aldehyde groups at their surface, allowing you to conjugate a wide variety of reagents using a simple reductive amination protocol.

For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).

貨號
產品尺寸
6792001
1 mg
更多
6792002
5 mg
更多
6792003
50 mg
更多
Request Technical Support

請輸入有效數量

請登錄以添加收藏夾。

購物車為空

詳細信息

Unconjugated AlphaPlex 645 (Samarium) Acceptor beads bear reactive aldehyde groups at their surface, allowing you to conjugate a wide variety of reagents using a simple reductive amination protocol. AlphaPlex is a multiplexing no-wash ELISA alternative and can be used for applications such as:

  • Analyte detection
  • Protein-protein interactions
  • Protein-DNA interactions
  • Protein-RNA interactions
  • Protein-small molecule interactions
  • Protein detection assays
  • Antibody detection assays
  • Antibody binding
  • Immunogenicity assays
  • Enzymatic assays
  • Other immunoassays

AlphaPlex Acceptor beads are intended to be used in multiplexing assays, in conjunction with AlphaLISA Acceptor beads and Alpha Donor beads. In a typical Alpha assay, 1 mg of Acceptor beads is sufficient to run 1,000-2,000 wells using a 50 µL reaction volume.

規格

抗體偶聯物 Unconjugated
自動化兼容 Yes
產品品牌名稱 AlphaPlex
運輸條件 藍冰
產品尺寸 50 mg
資源
  • 所有

產品手冊

應用文獻

Development of Pharmacokinetic (PK) Assays for Detecting Biosimilars Targeting TNF alpha using AlphaLISA

Anti-inflammatory monoclonal antibody drugs that specifically target TNFα, such as Humira®, have been highly successful in the market. As patents expire on these top-selling drugs, effort has been placed on developing biosimilars. Biosimilars differ from small molecule generi ...

PDF 2 MB

應用簡報

Eight Limitations of ELISA and How to Overcome Them Using Alternative Technologies

The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater ...

PDF 1 MB
Baidu
map